Aethlon Medical AEMD
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Aethlon Medical (AEMD)
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.4366Market Cap
$6.31 MillionPrice-Earnings Ratio
-2.18Total Outstanding Shares
14.46 Million SharesTotal Employees
14Dividend
No dividendIPO Date
March 4, 1999SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQType
Common StockHeadquarters
11555 sorrento valley road, suite 203, San diego, CA, 92121Homepage
https://www.aethlonmedical.com
Historical Stock Splits
If you bought 7,500 shares of AEMD before April 14, 2015, you'd have 1 share today.
Execution Date | Split Amount |
---|---|
October 5, 2023 | 1-for-10 (Reverse Split) |
October 15, 2019 | 1-for-15 (Reverse Split) |
April 14, 2015 | 1-for-50 (Reverse Split) |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $-3,832 |
Net Cash Flow From Operating Activities, Continuing | $-2.21 Million |
Net Cash Flow From Operating Activities | $-2.21 Million |
Exchange Gains/Losses | $5,085 |
Net Cash Flow, Continuing | $-10,170 |
Net Cash Flow From Investing Activities | $2.21 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations After Tax | $-2.81 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Preferred Stock Dividends And Other Adjustments | $0 |
Net Income/Loss Available To Common Stockholders, Basic | $-2.81 Million |
Net Income/Loss Attributable To Parent | $-2.81 Million |
Revenues | $0 |
Comprehensive Income
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Other Comprehensive Income/Loss | $3,804 |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Noncontrolling Interest | $0 |
Other Non-current Assets | $865,630 |
Accounts Payable | $922,888 |
Equity Attributable To Parent | $6.02 Million |
Current Liabilities | $2.33 Million |
Liabilities And Equity | $8.85 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Recent Headlines From The Web
Latest news, press releases, and media coverage about AEMD from trusted financial sources
Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.